We are on the edge of a new era for rare diseases drugs but translation from research to preclinical development is incredibly poor.
Ampleia's commitments
WHY DO THEY FAIL ?
Secure sustainable funding
Inject seed funding into preclinical developments to reach value-creation milestone
Lack of hard skills
Initiate the translation from Day 1
In-house project management team specialized in translation from research to clinics
Lack of entrepreneurial mindset
Ensure human factor is not a failure factor anymore
Coach the founders, support them through NewCo creation, secure the IP, BD and fundraising
OUR LEGACY
A relentless partner to address rare diseases
rare diseases
since 1958
550+ FTEs and 215k+ volunteers
€1.7b invested in R&D for rare diseases
Renown expertise
to develop programs
for rare diseases
Network of 6,000+ medical and scientific experts in rare diseases and across all technology modalities
38 clinical trials on-going or under preparation on 28 different indications
Up to 200 new research projects funded every year
An association with a proven track-record
as venture-builder
Creation of Genosafe in 2003 – CRO for gene and cell therapy
Creation of BIMR in 2013 with BPIfrance Investment fund for rare diseases and innovative therapies – 7 companies supported
Creation of Atamyo in 2020 – Gene therapy biotech for muscular dystrophies
Contributed to the creation of 600+ direct jobs
